Vanda Pharmaceuticals Inc. - VNDA - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: June 16, 2013

Vanda Pharmaceuticals Inc. - SIC # 2834

Ticker	Exchange	SIC #	Website	Latest Ticker
VNDA	Nasdaq	2834	http://www.vandapharma.com/	11.23 0.00
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Vanda Pharmaceuticals Inc. Vanda says Phase III study data shows cortisol rhythm restoration - Jun 17th, 2013 5:06 pm Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder - Jun 17th, 2013 5:00 pm Nasdaq stocks posting largest percentage increases - Jun 17th, 2013 4:05 pm White Collar Criminals Love Biotech Stocks - Jun 16th, 2013 5:00 pm Assessing Raptor Pharmaceutical's Agreement With HealthCare Royalty Partners - Jun 14th, 2013 10:52 am What are hedge funds buying these days? - Jun 14th, 2013 10:51 am 3 Stocks Near 52-Week Highs Worth Selling - Jun 13th, 2013 3:33 pm 3 longs and 3 shorts to watch - Jun 12th, 2013 1:22 pm Put Options Active On AmerisourceBergen - Jun 11th, 2013 12:28 pm Vanda Pharmaceuticals: A Small-Cap Biotech With A Pipeline Allowing For Long-Term Growth - Jun 6th, 2013 11:04 am Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder - Jun 5th, 2013 7:00 pm Major confidence in Vanda Pharma - Jun 5th, 2013 2:47 am [video] Where to Invest Now - Jun 4th, 2013 12:16 pm 4 Healthcare Stock Stories To Close Out the Week - May 31st, 2013 4:25 pm Vanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference - May 31st, 2013 2:00 pm Traders selling puts as stocks churn - May 31st, 2013 11:21 am Squeezing pennies in Vanda Pharma - May 31st, 2013 9:41 am Vanda files for approval of sleep disorder drug - May 31st, 2013 7:00 am Vanda files for approval of sleep disorder drug - May 31st, 2013 7:00 am Vanda Pharmaceuticals submits NDA to FDA for Tasimelteon - May 31st, 2013 4:58 am View All Current Headlines >>